EGFR and hepatocellular carcinoma: Additionally, given the low objective response rate of EGFR TKIs in HCC (6.6–30%) (22, 23), the high cost of such molecular testing is not reimbursed by commercial or National Health Insurance in Taiwan, preventing its adoption as a routine clinical practice.